leadf
logo-loader
viewAstraZeneca

AstraZeneca posts positive late-stage trial results for asthma treatment

The drug candidate, developed with Amgen, was found to be effective and safe

AstraZeneca - AstraZeneca posts positive late-stage trial results for asthma treatment

AstraZeneca PLC (LON:AZN) has announced positive late-stage trial results for its drug candidate, tezepelumab for patients with severe, uncontrolled asthma.

The FTSE 100 group said phase III trials met the primary endpoint, which is the main result the pharma company was seeking, by combining tezepelumab to the standard of care.

READ: AstraZeneca receives EU approval for leukaemia treatment

The group said it demonstrated a statistically significant and clinically meaningful reduction in the asthma exacerbation rate over the course of a year, compared to the patients on a placebo.

There were no clinically meaningful differences in safety results between the tezepelumab and placebo groups.

The treatment, which is being developed by AstraZeneca in collaboration with US biotech Amgen, was granted Breakthrough Therapy Designation by the US Food and Drug Administration in 2018. It blocks the action of thymic stromal lymphopoietin, a protein that plays a key role across the spectrum of asthma inflammation.

The firm said severe asthma affects 34mln people worldwide, and many patients continue to experience symptoms and frequent episodes despite the use of high-dose asthma controller medicines, biologic therapies and oral corticosteroids.

Shares rose 2% to 8,451.72p on Tuesday morning.

--Adds shares--

Quick facts: AstraZeneca

Price: 7832.4829 GBX

LSE:AZN
Market: LSE
Market Cap: £102.78 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO report double-digit revenue growth and a more than doubling of profit

IXICO PLC's (LON:IXI) CEO Giulio Cerroni joins Proactive London's Katie Pilbeam to discuss the financial results for the year which ended 30 September 2020.  Cerroni talks through the strong double-digit revenue growth and the more than doubling of profit.  He goes on to explain...

1 hour, 22 minutes ago

2 min read